Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Conditions
- Endometrial Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Dedifferentiated Carcinoma
- Endometrial Endometrioid Adenocarcinoma
- Endometrial Mixed Cell Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Endometrial Undifferentiated Carcinoma
- Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
Interventions
- PROCEDURE: Biospecimen Collection
- DRUG: Carboplatin
- PROCEDURE: Computed Tomography
- PROCEDURE: Echocardiography Test
- RADIATION: High-Dose-Rate Vaginal Cuff Brachytherapy
- DRUG: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
- PROCEDURE: Multigated Acquisition Scan
- DRUG: Paclitaxel
- OTHER: Survey Administration
- DRUG: Trastuzumab/Hyaluronidase-oysk
Sponsor
National Cancer Institute (NCI)
Collaborators